Showing 1 - 15 results of 15 for search 'Jon T. Giles', query time: 0.06s
Refine Results
-
1
-
2
-
3
Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. by Jon T Giles, Erika Darrah, Sonye Danoff, Cheilonda Johnson, Felipe Andrade, Antony Rosen, Joan M Bathon
Published 2014-01-01
Article -
4
-
5
-
6
-
7
-
8
Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients by Elizabeth Park, Jon T. Giles, Thania Perez-Recio, Paloma Pina, Christopher Depender, Yevgeniya Gartshteyn, Anca D. Askanase, Joan Bathon, Laura Geraldino-Pardilla
Published 2021-10-01
Article -
9
Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis by Daniela Graham, Philip S Helliwell, Christopher Ritchlin, Alexis Ogdie, Jon T Giles, Rebecca Germino, Lori Stockert, Pamela Young, Wael Joseph, Rajiv Mundayat, Juan J Gómez-Reino
Published 2021-04-01
Article -
10
Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis by Erika Darrah, Jon T. Giles, Ryan L. Davis, Pooja Naik, Hong Wang, Maximilian F. Konig, Laura C. Cappelli, Clifton O. Bingham, Sonye K. Danoff, Felipe Andrade
Published 2018-11-01
Article -
11
Plasma adiponectin levels are associated with circulating inflammatory cytokines in autoantibody positive first-degree relatives of rheumatoid arthritis patients. by Jan M Hughes-Austin, Kevin D Deane, Jon T Giles, Lezlie A Derber, Gary O Zerbe, Dana M Dabelea, Jeremy Sokolove, William H Robinson, V Michael Holers, Jill M Norris
Published 2018-01-01
Article -
12
Identification of novel biomarkers for the prediction of subclinical coronary artery atherosclerosis in patients with rheumatoid arthritis: an exploratory analysis by Joan M. Bathon, Michael Centola, Xiaoqian Liu, Zhicheng Jin, Weihua Ji, Nicholas S. Knowlton, Iván Ferraz-Amaro, Qin Fu, Jon T. Giles, Mary Chester Wasko, C. Michael Stein, Jennifer E. Van Eyk
Published 2023-10-01
Article -
13
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 rand... by Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri
Published 2024-05-01
Article -
14
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years by Christina Charles-Schoeman, Jon T. Giles, Nancy E. Lane, Ernest Choy, Daniel E. Furst, Jiří Vencovský, Anthony G. Wilson, Gerd R. Burmester, Derek Coombs, Sara K. Penn, Nasser Khan, Jillian B. Yee, Kassim Rahawi, Iain B. McInnes
Published 2024-01-01
Article -
15
Testing the Effects of Disease‐Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial by Jon T. Giles, Pamela M. Rist, Katherine P. Liao, Ahmed Tawakol, Zahi A. Fayad, Venkatesh Mani, Nina P. Paynter, Paul M. Ridker, Robert J. Glynn, Fengxin Lu, Rachel Broderick, Meredith Murray, Kathleen M. M. Vanni, Daniel H. Solomon, Joan M. Bathon
Published 2021-06-01
Article